T2 Biosystems (TTOO) Receives News Sentiment Score of 0.24

Media coverage about T2 Biosystems (NASDAQ:TTOO) has trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. T2 Biosystems earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 46.2627114336087 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news articles that may have effected Accern’s scoring:

T2 Biosystems (TTOO) opened at $3.97 on Tuesday. T2 Biosystems has a fifty-two week low of $2.50 and a fifty-two week high of $7.07. The company has a quick ratio of 5.28, a current ratio of 5.40 and a debt-to-equity ratio of 2.25.

T2 Biosystems (NASDAQ:TTOO) last released its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.04. The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $1.10 million. T2 Biosystems had a negative net margin of 1,497.70% and a negative return on equity of 244.82%. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. equities analysts expect that T2 Biosystems will post -1.88 EPS for the current fiscal year.

TTOO has been the subject of a number of research reports. ValuEngine raised shares of T2 Biosystems from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 13th. HC Wainwright initiated coverage on shares of T2 Biosystems in a research report on Wednesday, October 18th. They set a “buy” rating and a $8.00 target price for the company. Zacks Investment Research raised shares of T2 Biosystems from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. Finally, Canaccord Genuity reissued a “buy” rating and set a $6.00 target price on shares of T2 Biosystems in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $6.54.

ILLEGAL ACTIVITY WARNING: “T2 Biosystems (TTOO) Receives News Sentiment Score of 0.24” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/11/14/t2-biosystems-ttoo-receives-news-sentiment-score-of-0-24.html.

About T2 Biosystems

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Insider Buying and Selling by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply